Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis

被引:27
作者
Lipton, RB
Pascual, J
Goadsby, PJ
Massiou, H
McCarroll, KA
Vandormael, K
Jiang, KH
Lines, CR
机构
[1] Innovat Med Res Inc, Stamford, CT 06905 USA
[2] Albert Einstein Coll Med, Bronx, NY USA
[3] Univ Hosp Marques de Valdecilla, Santander, Spain
[4] Neurol Inst, London, England
[5] Hop Lariboisiere, F-75475 Paris, France
[6] Merck Res Labs, West Point, PA USA
来源
HEADACHE | 2001年 / 41卷 / 08期
关键词
rizatriptan; sumatriptan; naratriptan; zolmitriptan; 5-HT1B/1D receptor agonists; migraine; nausea; baseline; emergent;
D O I
10.1046/j.1526-4610.2001.01139.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack. Methods.-Data from five randomized, placebo-controlled, double-blind clinical trials in which oral rizatriptan 10 mg was directly compared with oral sumatriptan 100 mg (N = 772), 50 mg (N = 1168), 25 mg (N = 1180), naratriptan 2.5 mg (N = 406), or zolmitriptan 2.5 mg (N = 571) for the acute treatment of a migraine attack were retrospectively analyzed. Migraine was diagnosed according to International Headache Society criteria. Presence or absence of nausea was recorded at baseline and at 0.5, 1, 1.5, and 2 hours after dosing. The end points analyzed were relief of nausea in those who had it at baseline and emergence of nausea in those who were free of it at baseline. Treatments were compared using odds ratios estimated from logistic regression models at 2 hours, and averaged odds ratios for the first 2 hours posttreatment. Results.-Approximately 60% of patients in each treatment group had nausea at baseline. In those patients with nausea at baseline, significantly more patients treated with rizatriptan 10 mg were free of nausea at 2 hours compared with sumatriptan 100 mg (66% versus 58%, P=.043), sumatriptan 50 mg (68% versus 57%, P=.010), sumatriptan 25 mg (68% versus 59%, P=.017), and naratriptan 2.5 mg (59% versus 45%, P=.014). Averaging over the four posttreatment time points in the first 2 hours, significantly more patients treated with rizatriptan 10 mg were free of nausea compared with sumatriptan 100 mg (P=.004), sumatriptan 50 mg (P=.001), and naratriptan 2.5 mg (P=.015). No significant differences in nausea relief were seen between rizatriptan 10 mg and zolmitriptan 2.5 mg, either at 2 hours (65% versus 61%, P=.210) or over the first 2 hours (P=.781). Rates of treatment-emergent nausea at 2 hours ranged from 11% to 18% with placebo, from 5% to 13% with rizatriptan 10 mg, and from 10% to 20% with other comparator triptans. Conclusions.-Oral rizatriptan 10 mg was more effective than oral sumatriptan and naratriptan at eliminating nausea within 2 hours in patients who had it at baseline. Rates of emergent nausea in patients who were free of it at baseline were low, and no consistent differences were observed between active treatments.
引用
收藏
页码:754 / 763
页数:10
相关论文
共 21 条
  • [1] ADELMAN JU, IN PRESS NEUROLOGY
  • [2] Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine
    Bomhof, M
    Paz, J
    Legg, N
    Allen, C
    Vandormael, K
    Patel, K
    [J]. EUROPEAN NEUROLOGY, 1999, 42 (03) : 173 - 179
  • [3] A PHASE-II MULTICENTER DOSE-FINDING, EFFICACY AND SAFETY TRIAL OF IPSAPIRONE IN OUTPATIENTS WITH GENERALIZED ANXIETY DISORDER
    CUTLER, NR
    HESSELINK, JMK
    SRAMEK, JJ
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1994, 18 (03) : 447 - 463
  • [4] Pathophysiology and pharmacology of migraine.: Is there a place for antiemetics in future treatment strategies?
    Dahlöf, CGH
    Hargreaves, RJ
    [J]. CEPHALALGIA, 1998, 18 (09) : 593 - 604
  • [5] Serotonin 5-HT1B/1D receptor agonists in migraine -: Comparative pharmacology and its therapeutic implications
    Goadsby, PJ
    [J]. CNS DRUGS, 1998, 10 (04) : 271 - 286
  • [6] Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
    Goadsby, PJ
    Ferrari, MD
    Olesen, J
    Stovner, LJ
    Senard, JM
    Jackson, NC
    Poole, PH
    [J]. NEUROLOGY, 2000, 54 (01) : 156 - 163
  • [7] Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
    Goldstein, J
    Ryan, R
    Jiang, KH
    Getson, A
    Norman, B
    Block, GA
    Lines, C
    [J]. HEADACHE, 1998, 38 (10): : 737 - 747
  • [8] AN OPEN STUDY OF ORAL FLESINOXAN, A 5-HT(1A) RECEPTOR AGONIST, IN TREATMENT-RESISTANT DEPRESSION
    GROF, P
    JOFFE, R
    KENNEDY, S
    PERSAD, E
    SYROTIUK, J
    BRADFORD, D
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 (03) : 167 - 172
  • [9] INHIBITION BY SUMATRIPTAN OF CENTRAL TRIGEMINAL NEURONS ONLY AFTER BLOOD-BRAIN-BARRIER DISRUPTION
    KAUBE, H
    HOSKIN, KL
    GOADSBY, PJ
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (03) : 788 - 792
  • [10] LIPTON RB, 2001, CEPHALALGIA, V21, P422